{"protocolSection": {"identificationModule": {"nctId": "NCT03695094", "orgStudyIdInfo": {"id": "UP0070"}, "secondaryIdInfos": [{"id": "2018-001941-16", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "UCB Pharma", "class": "INDUSTRY"}, "briefTitle": "A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil", "officialTitle": "A Multicenter, Open-label, Parallel-group Study in Study Participants With Epilepsy, to Evaluate the Effect of Oxcarbazepine on the Pharmacokinetics, Safety, and Tolerability of Padsevonil"}, "statusModule": {"statusVerifiedDate": "2020-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-09-18", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-05-18", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-05-30", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-09-14", "studyFirstSubmitQcDate": "2018-10-02", "studyFirstPostDateStruct": {"date": "2018-10-03", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2020-05-18", "resultsFirstSubmitQcDate": "2020-05-18", "resultsFirstPostDateStruct": {"date": "2020-06-04", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-05-18", "lastUpdatePostDateStruct": {"date": "2020-06-04", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "UCB Biopharma S.P.R.L.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of the study is to evaluate the effect of stable coadministered oxcarbazepine (OXC), on the pharmacokinetics (PK), safety, tolerability of padsevonil (PSL) and the plasma PK of PSL metabolites, UCB1431322-000 and UCB1447499-000, in study participants with epilepsy compared with study participants co-medicated with stable doses of levetiracetam (LEV), lamotrigine (LTG) or brivaracetam (BRV) therapy."}, "conditionsModule": {"conditions": ["Epilepsy"], "keywords": ["Epilepsy", "Phase 1", "padsevonil"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 31, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Cohort 1", "type": "EXPERIMENTAL", "description": "Cohort 1 (Inducers): Study participants on stable therapy with oxcarbazepine (OXC) either as monotherapy or adjunctive to levetiracetam (LEV), lamotrigine (LTG), or brivaracetam (BRV). OXC may be used as monotherapy or in combination with 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) will be dosed to steady state and the effect of background therapy on PSL pharmacokinetics will be assessed at steady state.", "interventionNames": ["Drug: Padsevonil", "Drug: Oxcarbazepine", "Drug: Levetiracetam", "Drug: Lamotrigine", "Drug: Brivaracetam"]}, {"label": "Cohort 2", "type": "EXPERIMENTAL", "description": "Cohort 2 (Neutral): Study participants on stable therapy with lamotrigine (LTG), levetiracetam (LEV), or brivaracetam (BRV). LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. Padsevonil (PSL) will be dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics will be assessed at steady state.", "interventionNames": ["Drug: Padsevonil", "Drug: Levetiracetam", "Drug: Lamotrigine", "Drug: Brivaracetam"]}], "interventions": [{"type": "DRUG", "name": "Padsevonil", "description": "Padsevonil (PSL) will be dosed to steady state and the effect of background therapies on pharmacokinetics will be assessed", "armGroupLabels": ["Cohort 1", "Cohort 2"], "otherNames": ["PSL", "UCB0942"]}, {"type": "DRUG", "name": "Oxcarbazepine", "description": "Concomitant administration of oxcarbazepine (OXC) at therapeutic dosage", "armGroupLabels": ["Cohort 1"], "otherNames": ["OXC"]}, {"type": "DRUG", "name": "Levetiracetam", "description": "Concomitant administration of levetiracetam (LEV) at therapeutic dosage", "armGroupLabels": ["Cohort 1", "Cohort 2"], "otherNames": ["LEV"]}, {"type": "DRUG", "name": "Lamotrigine", "description": "Concomitant administration of lamotrigine (LTG) at therapeutic dosage", "armGroupLabels": ["Cohort 1", "Cohort 2"], "otherNames": ["LTG"]}, {"type": "DRUG", "name": "Brivaracetam", "description": "Concomitant administration of brivaracetam (BRV) at therapeutic dosage", "armGroupLabels": ["Cohort 1", "Cohort 2"], "otherNames": ["BRV"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Maximum Observed Plasma Concentration (Cmax) of Padsevonil (PSL) During the Study", "description": "The Cmax for Padsevonil in plasma was expressed in nanograms per milliliter (ng/mL).", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose"}, {"measure": "The Time to Reach Maximum Concentration (Tmax) for Padsevonil During the Study", "description": "The tmax for Padsevonil in plasma was expressed in hours (hr).", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose"}, {"measure": "The Area Under the Plasma Concentration Time Curve (AUCtau) Over a Dosing Interval for PSL", "description": "The AUCtau for Padsevonil in plasma was expressed in hours times nanograms per milliliter (hr\\*ng/mL).", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose"}, {"measure": "The Apparent Total Plasma Clearance at Steady-state (CL/Fss) for PSL During the Study", "description": "The CL/Fss for Padsevonil in plasma was expressed in liters per hour (L/hr). Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose"}], "secondaryOutcomes": [{"measure": "Trough Plasma Concentration of Mono Hydroxy Derivate (MHD) in the Inducers Group Before, During and After Dosing to Steady State With PSL", "description": "The trough plasma concentration of MHD with PSL was expressed in micrograms per milliliter (\u00b5g/mL).\n\nGeometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).", "timeFrame": "Trough plasma samples were taken prior to the morning dose of OXC on Day -1, Day 1 through Day 20 (+/-1)"}, {"measure": "The Maximum Observed Plasma Concentration (Cmax) for UCB1431322-000 During the Study", "description": "The Cmax for UCB1431322-000 in plasma was expressed in nanograms per milliliter (ng/mL).\n\nGeometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose"}, {"measure": "The Time to Reach Maximum Concentration (Tmax) for UCB1431322-000 During the Study", "description": "The tmax for UCB1431322-000 in plasma was expressed in hours (hr).", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose"}, {"measure": "The Area Under the Curve (AUCtau) Over a Dosing Interval for UCB1431322-000 During the Study", "description": "The AUCtau for UCB1431322-000 in plasma in was expressed in hours times nanograms per milliliter (hr\\*ng/mL).\n\nGeometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose"}, {"measure": "The Ratio of PSL Metabolite UCB1431322-000 to PSL Based on the Area Under the Curve (AUCtau) During the Study", "description": "Metabolite-to-Parent Ratios were corrected for differences in molecular weight. Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose"}, {"measure": "The Maximum Observed Plasma Concentration (Cmax) for UCB1447499-000 During the Study", "description": "The Cmax for UCB1447499-000 in plasma was expressed in ng/mL. Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose"}, {"measure": "The Time to Reach Maximum Concentration (Tmax) for UCB1447499-000 During the Study", "description": "The tmax for UCB1447499-000 in plasma was expressed in hr.", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose"}, {"measure": "The Area Under the Curve (AUCtau) Over a Dosing Interval for UCB1447499-000 During the Study", "description": "The AUCtau for UCB1447499-000 in plasma was expressed in hr\\*ng/mL. Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose"}, {"measure": "The Ratio of PSL Metabolite UCB1447499-000 to PSL Based on the Area Under the Curve (AUCtau)", "description": "Metabolite-to-Parent Ratios were corrected for differences in molecular weight. Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose"}, {"measure": "Percentage of Participants With at Least One Adverse Event (AE) During the Study", "description": "An AE was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.", "timeFrame": "From screening (Day -28 to Day -2) up to end of study (EOS) visit day 20 (+/-1)"}, {"measure": "Percentage of Participants With at Least One Serious Adverse Event (SAE) During the Study", "description": "A SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required in patient hospitalization or prolongation of existing hospitalization, was a congenital anomaly or birth defect, was an infection that requires treatment parenteral antibiotics or other important medical events which based on medical or scientific judgement could jeopardize the patients, or could require medical or surgical intervention to prevent any of the above.", "timeFrame": "From screening (Day -28 to Day -2) up to end of study (EOS) visit day 20 (+/-1)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Study participant is male or female between 18 to 64 years of age, inclusive, with a diagnosis of epilepsy according to the International League Against Epilepsy (ILAE) classification\n* Study participant is currently treated for epilepsy with stable doses of the following for at least 3 months:\n\n  1. Inducers Group: Oxcarbazepine (OXC) (at least 1200 mg/day as monotherapy or in combination with brivaracetam (BRV) \\[up to 200 mg/day\\], levetiracetam (LEV) \\[at least 1 g/day\\] or lamotrigine (LTG) \\[at least 150 mg/day\\]); or\n  2. Neutral (control) Group: LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG)\n* Study participant in the Inducers Group is taking OXC and has a trough OXC metabolite Mono Hydroxy Derivate (MHD) plasma level in the target range (\u226512.0 to \u226435.0 mcg/mL)\n* Study participant has clinical laboratory test results within the local reference ranges or values are considered as not clinically relevant by the Investigator and approved by the UCB Study Physician\n* Study participant has a body mass index (BMI) of 18 to 35 kg/m\u00b2, inclusive, with a body weight of at least 50 kg (male) or 45 kg (female)\n* Female study participant has a negative serum pregnancy test at the Screening Visit and agrees to use an efficient form of contraception for the duration of the study (unless menopausal \\[defined as no menses for 12 months without an alternative medical cause\\]; a high follicle-stimulating hormone level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy). -Male study participant agrees that, during the study period, when having sexual intercourse with a woman of childbearing potential, he will use an efficient barrier contraceptive (condom plus spermicide) AND that the respective partner will use an additional efficient contraceptive method (eg, oral pills, intrauterine device, intrauterine hormone-releasing systems, or diaphragm, and spermicide)\n\nExclusion Criteria:\n\n* Study participant has participated in another study of an investigational medication (or a medical device) within the last 3 months before screening (or 5 half-lives, whichever is longer) or is currently participating in another study of an investigational medication (or a medical device)\n* Study participant has a known hypersensitivity to any components of the IMP as stated in this protocol\n* Study participant has any medical condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study\n* Study participant has a history of status epilepticus during the last year\n* Study participant has any clinically relevant electrocardiogram (ECG) finding at the Screening Visit or at Baseline\n* Study participant has received any prescription or nonprescription medicines, including enzyme inhibitors or inducers, over the counter (OTC) remedies, herbal and dietary supplements (including St. John's Wort), or vitamins up to 2 weeks or 5 half-lives of the respective drug (whichever is longer) before the first administration of IMP and during the clinical part of the study, unless required to treat an Adverse event (AE). This does not include allowed antiepileptic drugs (AEDs) per the protocol, oral contraceptives not exceeding 30 \u03bcg ethinyl estradiol or postmenopausal hormone replacement therapy or implants, patches, or IUDs/IUSs delivering progesterone (for female study participants)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "64 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "UCB Cares", "affiliation": "001 844 599 2273 (UCB)", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Up0070 101", "city": "Sofia", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Up0070 401", "city": "Leiden", "country": "Netherlands", "geoPoint": {"lat": 52.15833, "lon": 4.49306}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study included a Screening Period (Day -28 to Day -2), a Baseline Visit (Day -1), a Treatment Period (Day 1 to Day 12) and a Safety Follow-Up Period Day (13 to Day 20\u00b11).\n\nParticipant Flow refers to the Full Analysis Set.", "recruitmentDetails": "The study started to enroll patients in September 2018 and concluded in May 2019.", "groups": [{"id": "FG000", "title": "Group 1 (Inducers)", "description": "Participants were on stable therapy with oxcarbazepine (OXC), at least 1200 milligrams per day (mg/day), which could be used as monotherapy or adjunctive to 1 or more of levetiracetam (LEV), lamotrigine (LTG), or brivaracetam (BRV). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state."}, {"id": "FG001", "title": "Group 2 (Neutral [Control])", "description": "Participants were on stable therapy with LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Baseline Characteristics refer to the Full Analysis Set (FAS) which consisted of all study participants who signed the Informed Consent Form (ICF) and received at least 1 dose of investigational medicinal product (padsevonil).", "groups": [{"id": "BG000", "title": "Group 1 (Inducers)", "description": "Participants were on stable therapy with oxcarbazepine (OXC), at least 1200 milligrams per day (mg/day), which could be used as monotherapy or adjunctive to 1 or more of levetiracetam (LEV), lamotrigine (LTG), or brivaracetam (BRV). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state."}, {"id": "BG001", "title": "Group 2 (Neutral [Control])", "description": "Participants were on stable therapy with LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state."}, {"id": "BG002", "title": "Total Title"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "31"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "31"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "41.4", "spread": "12.1"}, {"groupId": "BG001", "value": "33.6", "spread": "10.4"}, {"groupId": "BG002", "value": "37.6", "spread": "11.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "16"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "15"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "White", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "30"}]}, {"title": "Other or mixed", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Maximum Observed Plasma Concentration (Cmax) of Padsevonil (PSL) During the Study", "description": "The Cmax for Padsevonil in plasma was expressed in nanograms per milliliter (ng/mL).", "populationDescription": "The Pharmacokinetic Per-Protocol Set (PK-PPS) was a subset of the Full Analysis Set (FAS), consisting of study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ng/mL", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose", "groups": [{"id": "OG000", "title": "Group 1 (Inducers) (PK-PPS)", "description": "Participants were on stable therapy OXC, at least 1200 mg/day, which could be used as monotherapy or adjunctive to 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the Pharmacokinetic Per-Protocol Set (PK-PPS)."}, {"id": "OG001", "title": "Group 2 (Neutral [Control]) (PK-PPS)", "description": "Participants were on stable therapy with LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the PK-PPS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1210", "lowerLimit": "1010", "upperLimit": "1450"}, {"groupId": "OG001", "value": "1670", "lowerLimit": "1390", "upperLimit": "2000"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The analysis of variance model (ANOVA) included the fixed effects of treatment group. The natural logs were taken of the dependent variables and were back-transformed after the analysis. The geometric mean ratio and the respective 90% confidence interval (CI) was derived for the Inducers group vs the Neutral-control group from the ANOVA model using least-squares means difference.", "nonInferiorityType": "OTHER", "statisticalMethod": "ANOVA", "paramType": "Geometric mean ratio", "paramValue": "0.725", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.586", "ciUpperLimit": "0.896"}]}, {"type": "PRIMARY", "title": "The Time to Reach Maximum Concentration (Tmax) for Padsevonil During the Study", "description": "The tmax for Padsevonil in plasma was expressed in hours (hr).", "populationDescription": "The Pharmacokinetic Per-Protocol Set (PK-PPS) was a subset of the Full Analysis Set (FAS), consisting of study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hr", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose", "groups": [{"id": "OG000", "title": "Group 1 (Inducers) (PK-PPS)", "description": "Participants were on stable therapy OXC, at least 1200 mg/day, which could be used as monotherapy or adjunctive to 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the Pharmacokinetic Per-Protocol Set (PK-PPS)."}, {"id": "OG001", "title": "Group 2 (Neutral [Control]) (PK-PPS)", "description": "Participants were on stable therapy with LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the PK-PPS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.500", "lowerLimit": "1.00", "upperLimit": "4.00"}, {"groupId": "OG001", "value": "2.000", "lowerLimit": "0.500", "upperLimit": "4.00"}]}]}]}, {"type": "PRIMARY", "title": "The Area Under the Plasma Concentration Time Curve (AUCtau) Over a Dosing Interval for PSL", "description": "The AUCtau for Padsevonil in plasma was expressed in hours times nanograms per milliliter (hr\\*ng/mL).", "populationDescription": "The Pharmacokinetic Per-Protocol Set (PK-PPS) was a subset of the Full Analysis Set (FAS), consisting of study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "hr*ng/mL", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose", "groups": [{"id": "OG000", "title": "Group 1 (Inducers) (PK-PPS)", "description": "Participants were on stable therapy OXC, at least 1200 mg/day, which could be used as monotherapy or adjunctive to 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the Pharmacokinetic Per-Protocol Set (PK-PPS)."}, {"id": "OG001", "title": "Group 2 (Neutral [Control]) (PK-PPS)", "description": "Participants were on stable therapy with LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the PK-PPS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5301", "lowerLimit": "4350", "upperLimit": "6460"}, {"groupId": "OG001", "value": "8339", "lowerLimit": "6850", "upperLimit": "10200"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The analysis of variance model (ANOVA) included the fixed effects of treatment group. The natural logs were taken of the dependent variables and were back-transformed after the analysis. The geometric mean ratio and the respective 90% confidence interval (CI) was derived for the Inducers group vs the Neutral-control group from the ANOVA model using least-squares means difference.", "nonInferiorityType": "OTHER", "statisticalMethod": "ANOVA", "paramType": "Geometric mean ratio", "paramValue": "0.636", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.504", "ciUpperLimit": "0.801"}]}, {"type": "PRIMARY", "title": "The Apparent Total Plasma Clearance at Steady-state (CL/Fss) for PSL During the Study", "description": "The CL/Fss for Padsevonil in plasma was expressed in liters per hour (L/hr). Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).", "populationDescription": "The Pharmacokinetic Per-Protocol Set (PK-PPS) was a subset of the Full Analysis Set (FAS), consisting of study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "L/hr", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose", "groups": [{"id": "OG000", "title": "Group 1 (Inducers) (PK-PPS)", "description": "Participants were on stable therapy OXC, at least 1200 mg/day, which could be used as monotherapy or adjunctive to 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the Pharmacokinetic Per-Protocol Set (PK-PPS)."}, {"id": "OG001", "title": "Group 2 (Neutral [Control]) (PK-PPS)", "description": "Participants were on stable therapy with LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the PK-PPS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "75.44", "spread": "34.8"}, {"groupId": "OG001", "value": "47.94", "spread": "39.3"}]}]}]}, {"type": "SECONDARY", "title": "Trough Plasma Concentration of Mono Hydroxy Derivate (MHD) in the Inducers Group Before, During and After Dosing to Steady State With PSL", "description": "The trough plasma concentration of MHD with PSL was expressed in micrograms per milliliter (\u00b5g/mL).\n\nGeometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).", "populationDescription": "The Pharmacokinetic Per-Protocol Set (PK-PPS) was a subset of the Full Analysis Set (FAS), consisting of study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "\u00b5g/mL", "timeFrame": "Trough plasma samples were taken prior to the morning dose of OXC on Day -1, Day 1 through Day 20 (+/-1)", "groups": [{"id": "OG000", "title": "Group 1 (Inducers) (PK-PPS)", "description": "Participants were on stable therapy OXC, at least 1200 mg/day, which could be used as monotherapy or adjunctive to 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the Pharmacokinetic Per-Protocol Set (PK-PPS)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "classes": [{"title": "Day 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "14.9", "spread": "14.5"}]}]}, {"title": "Day 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "14.0", "spread": "21.6"}]}]}, {"title": "Day 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "14.9", "spread": "17.0"}]}]}, {"title": "Day 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "15.5", "spread": "16.0"}]}]}, {"title": "Day 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "15.2", "spread": "17.5"}]}]}, {"title": "Day 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "15.4", "spread": "18.1"}]}]}, {"title": "Day 7", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "15.4", "spread": "17.0"}]}]}, {"title": "Day 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "16.3", "spread": "16.1"}]}]}, {"title": "Day 9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "15.4", "spread": "13.2"}]}]}, {"title": "Day 10", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "15.5", "spread": "13.8"}]}]}, {"title": "Day 11", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "15.4", "spread": "18.6"}]}]}, {"title": "Day 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.8", "spread": "20.9"}]}]}, {"title": "Day 13", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11.3", "spread": "46.4"}]}]}]}, {"type": "SECONDARY", "title": "The Maximum Observed Plasma Concentration (Cmax) for UCB1431322-000 During the Study", "description": "The Cmax for UCB1431322-000 in plasma was expressed in nanograms per milliliter (ng/mL).\n\nGeometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).", "populationDescription": "The Pharmacokinetic Per-Protocol Set (PK-PPS) was a subset of the Full Analysis Set (FAS), consisting of study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose", "groups": [{"id": "OG000", "title": "Group 1 (Inducers) (PK-PPS)", "description": "Participants were on stable therapy OXC, at least 1200 mg/day, which could be used as monotherapy or adjunctive to 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the Pharmacokinetic Per-Protocol Set (PK-PPS)."}, {"id": "OG001", "title": "Group 2 (Neutral [Control]) (PK-PPS)", "description": "Participants were on stable therapy with LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the PK-PPS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1753", "spread": "21.7"}, {"groupId": "OG001", "value": "1700", "spread": "29.4"}]}]}]}, {"type": "SECONDARY", "title": "The Time to Reach Maximum Concentration (Tmax) for UCB1431322-000 During the Study", "description": "The tmax for UCB1431322-000 in plasma was expressed in hours (hr).", "populationDescription": "The Pharmacokinetic Per-Protocol Set (PK-PPS) was a subset of the Full Analysis Set (FAS), consisting of study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hr", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose", "groups": [{"id": "OG000", "title": "Group 1 (Inducers) (PK-PPS)", "description": "Participants were on stable therapy OXC, at least 1200 mg/day, which could be used as monotherapy or adjunctive to 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the Pharmacokinetic Per-Protocol Set (PK-PPS)."}, {"id": "OG001", "title": "Group 2 (Neutral [Control]) (PK-PPS)", "description": "Participants were on stable therapy with LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the PK-PPS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.500", "lowerLimit": "1.00", "upperLimit": "4.00"}, {"groupId": "OG001", "value": "3.500", "lowerLimit": "1.00", "upperLimit": "4.00"}]}]}]}, {"type": "SECONDARY", "title": "The Area Under the Curve (AUCtau) Over a Dosing Interval for UCB1431322-000 During the Study", "description": "The AUCtau for UCB1431322-000 in plasma in was expressed in hours times nanograms per milliliter (hr\\*ng/mL).\n\nGeometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).", "populationDescription": "The Pharmacokinetic Per-Protocol Set (PK-PPS) was a subset of the Full Analysis Set (FAS), consisting of study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "hr*ng/mL", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose", "groups": [{"id": "OG000", "title": "Group 1 (Inducers) (PK-PPS)", "description": "Participants were on stable therapy OXC, at least 1200 mg/day, which could be used as monotherapy or adjunctive to 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the Pharmacokinetic Per-Protocol Set (PK-PPS)."}, {"id": "OG001", "title": "Group 2 (Neutral [Control]) (PK-PPS)", "description": "Participants were on stable therapy with LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the PK-PPS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11720", "spread": "21.3"}, {"groupId": "OG001", "value": "11200", "spread": "30.7"}]}]}]}, {"type": "SECONDARY", "title": "The Ratio of PSL Metabolite UCB1431322-000 to PSL Based on the Area Under the Curve (AUCtau) During the Study", "description": "Metabolite-to-Parent Ratios were corrected for differences in molecular weight. Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).", "populationDescription": "The Pharmacokinetic Per-Protocol Set (PK-PPS) was a subset of the Full Analysis Set (FAS), consisting of study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ratio", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose", "groups": [{"id": "OG000", "title": "Group 1 (Inducers) (PK-PPS)", "description": "Participants were on stable therapy OXC, at least 1200 mg/day, which could be used as monotherapy or adjunctive to 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the Pharmacokinetic Per-Protocol Set (PK-PPS)."}, {"id": "OG001", "title": "Group 2 (Neutral [Control]) (PK-PPS)", "description": "Participants were on stable therapy with LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the PK-PPS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.283", "spread": "22.4"}, {"groupId": "OG001", "value": "1.386", "spread": "48.2"}]}]}]}, {"type": "SECONDARY", "title": "The Maximum Observed Plasma Concentration (Cmax) for UCB1447499-000 During the Study", "description": "The Cmax for UCB1447499-000 in plasma was expressed in ng/mL. Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).", "populationDescription": "The Pharmacokinetic Per-Protocol Set (PK-PPS) was a subset of the Full Analysis Set (FAS), consisting of study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose", "groups": [{"id": "OG000", "title": "Group 1 (Inducers) (PK-PPS)", "description": "Participants were on stable therapy OXC, at least 1200 mg/day, which could be used as monotherapy or adjunctive to 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the Pharmacokinetic Per-Protocol Set (PK-PPS)."}, {"id": "OG001", "title": "Group 2 (Neutral [Control]) (PK-PPS)", "description": "Participants were on stable therapy with LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the PK-PPS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "380.1", "spread": "37.8"}, {"groupId": "OG001", "value": "307.2", "spread": "32.6"}]}]}]}, {"type": "SECONDARY", "title": "The Time to Reach Maximum Concentration (Tmax) for UCB1447499-000 During the Study", "description": "The tmax for UCB1447499-000 in plasma was expressed in hr.", "populationDescription": "The Pharmacokinetic Per-Protocol Set (PK-PPS) was a subset of the Full Analysis Set (FAS), consisting of study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hr", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose", "groups": [{"id": "OG000", "title": "Group 1 (Inducers) (PK-PPS)", "description": "Participants were on stable therapy OXC, at least 1200 mg/day, which could be used as monotherapy or adjunctive to 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the Pharmacokinetic Per-Protocol Set (PK-PPS)."}, {"id": "OG001", "title": "Group 2 (Neutral [Control]) (PK-PPS)", "description": "Participants were on stable therapy with LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the PK-PPS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.000", "lowerLimit": "1.00", "upperLimit": "4.00"}, {"groupId": "OG001", "value": "2.000", "lowerLimit": "1.50", "upperLimit": "4.00"}]}]}]}, {"type": "SECONDARY", "title": "The Area Under the Curve (AUCtau) Over a Dosing Interval for UCB1447499-000 During the Study", "description": "The AUCtau for UCB1447499-000 in plasma was expressed in hr\\*ng/mL. Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).", "populationDescription": "The Pharmacokinetic Per-Protocol Set (PK-PPS) was a subset of the Full Analysis Set (FAS), consisting of study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "hr*ng/mL", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose", "groups": [{"id": "OG000", "title": "Group 1 (Inducers) (PK-PPS)", "description": "Participants were on stable therapy OXC, at least 1200 mg/day, which could be used as monotherapy or adjunctive to 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the Pharmacokinetic Per-Protocol Set (PK-PPS)."}, {"id": "OG001", "title": "Group 2 (Neutral [Control]) (PK-PPS)", "description": "Participants were on stable therapy with LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the PK-PPS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1854", "spread": "29.0"}, {"groupId": "OG001", "value": "1678", "spread": "28.2"}]}]}]}, {"type": "SECONDARY", "title": "The Ratio of PSL Metabolite UCB1447499-000 to PSL Based on the Area Under the Curve (AUCtau)", "description": "Metabolite-to-Parent Ratios were corrected for differences in molecular weight. Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged).", "populationDescription": "The Pharmacokinetic Per-Protocol Set (PK-PPS) was a subset of the Full Analysis Set (FAS), consisting of study participants who had no important protocol deviations affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ratio", "timeFrame": "Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose", "groups": [{"id": "OG000", "title": "Group 1 (Inducers) (PK-PPS)", "description": "Participants were on stable therapy OXC, at least 1200 mg/day, which could be used as monotherapy or adjunctive to 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the Pharmacokinetic Per-Protocol Set (PK-PPS)."}, {"id": "OG001", "title": "Group 2 (Neutral [Control]) (PK-PPS)", "description": "Participants were on stable therapy with LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the PK-PPS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.3492", "spread": "32.8"}, {"groupId": "OG001", "value": "0.2011", "spread": "45.7"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With at Least One Adverse Event (AE) During the Study", "description": "An AE was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.", "populationDescription": "The Full Analysis Set (FAS) consisted of all study participants who signed the ICF and received at least 1 dose of IMP.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "From screening (Day -28 to Day -2) up to end of study (EOS) visit day 20 (+/-1)", "groups": [{"id": "OG000", "title": "Group 1 (Inducers) (FAS)", "description": "Participants were on stable therapy with oxcarbazepine (OXC), at least 1200 mg/day, which could be used as monotherapy or adjunctive to 1 or more of levetiracetam (LEV), lamotrigine (LTG), or brivaracetam (BRV). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the Full Analysis Set (FAS)."}, {"id": "OG001", "title": "Group 2 (Neutral [Control]) (FAS)", "description": "Participants were on stable therapy with LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "100"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With at Least One Serious Adverse Event (SAE) During the Study", "description": "A SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required in patient hospitalization or prolongation of existing hospitalization, was a congenital anomaly or birth defect, was an infection that requires treatment parenteral antibiotics or other important medical events which based on medical or scientific judgement could jeopardize the patients, or could require medical or surgical intervention to prevent any of the above.", "populationDescription": "The Full Analysis Set (FAS) consisted of all study participants who signed the ICF and received at least 1 dose of IMP.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "From screening (Day -28 to Day -2) up to end of study (EOS) visit day 20 (+/-1)", "groups": [{"id": "OG000", "title": "Group 1 (Inducers) (FAS)", "description": "Participants were on stable therapy with oxcarbazepine (OXC), at least 1200 mg/day, which could be used as monotherapy or adjunctive to 1 or more of levetiracetam (LEV), lamotrigine (LTG), or brivaracetam (BRV). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the Full Analysis Set (FAS)."}, {"id": "OG001", "title": "Group 2 (Neutral [Control]) (FAS)", "description": "Participants were on stable therapy with LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Treatment Emergent Adverse events (TEAEs) were collected from the Baseline Visit (Day -1) until the Safety Follow-Up Period (Day 20\u00b11).", "description": "Only TEAEs occurring above the reporting threshold of 5% of participants in any treatment group are included in this summary.", "eventGroups": [{"id": "EG000", "title": "Group 1 (Inducers) (FAS)", "description": "Participants were on stable therapy with oxcarbazepine (OXC), at least 1200 mg/day, which could be used as monotherapy or adjunctive to 1 or more of levetiracetam (LEV), lamotrigine (LTG), or brivaracetam (BRV). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the Full Analysis Set (FAS).", "deathsNumAffected": 0, "deathsNumAtRisk": 16, "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 16, "otherNumAtRisk": 16}, {"id": "EG001", "title": "Group 2 (Neutral [Control]) (FAS)", "description": "Participants were on stable therapy with LTG (at least 150 mg/day monotherapy or adjunctive to LEV or BRV), LEV (at least 1 g/day monotherapy or adjunctive to LTG), or BRV (up to 200 mg/day adjunctive to LTG). Padsevonil (PSL) was dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics (PK) was assessed at steady state. Participants formed the FAS.", "deathsNumAffected": 0, "deathsNumAtRisk": 15, "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 15, "otherNumAtRisk": 15}], "otherEvents": [{"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Diplopia", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 15}]}, {"term": "Vision blurred", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 3, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 9, "numAffected": 4, "numAtRisk": 15}]}, {"term": "Hyperchlorhydria", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 15}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 18, "numAffected": 6, "numAtRisk": 15}]}, {"term": "Feeling drunk", "organSystem": "General disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 15}]}, {"term": "Gait disturbance", "organSystem": "General disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 15}]}, {"term": "Feeling cold", "organSystem": "General disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 15}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Chills", "organSystem": "General disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Crying", "organSystem": "General disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Feeling abnormal", "organSystem": "General disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Feeling jittery", "organSystem": "General disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Influenza like illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Injection site haematoma", "organSystem": "General disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Sluggishness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Procedural dizziness", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Procedural nausea", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Blood calcium decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Blood sodium decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Blood calcium increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Blood pressure increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Blood sodium increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Monocyte count increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Limb discomfort", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 6, "numAffected": 2, "numAtRisk": 15}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 12, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 53, "numAffected": 12, "numAtRisk": 15}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 9, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 62, "numAffected": 10, "numAtRisk": 15}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 8, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 23, "numAffected": 9, "numAtRisk": 15}]}, {"term": "Sudden onset of sleep", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 36, "numAffected": 8, "numAtRisk": 15}]}, {"term": "Amnesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 15}]}, {"term": "Disturbance in attention", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 8, "numAffected": 4, "numAtRisk": 15}]}, {"term": "Focal dyscognitive seizures", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 15}]}, {"term": "Head discomfort", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 15}]}, {"term": "Anterograde amnesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Coordination abnormal", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Dysgraphia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Facial paresis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Generalised tonic-clonic seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Memory impairment", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Paraesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Petit mal epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Slow response to stimuli", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Stupor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Agitation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 15}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 8, "numAffected": 4, "numAtRisk": 15}]}, {"term": "Disorientation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Irritability", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 15}]}, {"term": "Depressed mood", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 15}]}, {"term": "Abnormal dreams", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Bradyphrenia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 3, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Confusional state", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Euphoric mood", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Hallucination, visual", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Polyuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Dysmenorrhoea", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Hiccups", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 10, "numAffected": 3, "numAtRisk": 15}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA22.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "UCB", "organization": "Cares", "email": "clinicaltrials@ucb.com", "phone": "+1844 599", "phoneExt": "2273"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2018-06-08", "uploadDate": "2020-05-13T05:39", "filename": "Prot_000.pdf", "size": 3202361}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2018-10-26", "uploadDate": "2020-05-13T05:40", "filename": "SAP_001.pdf", "size": 1864909}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000004827", "term": "Epilepsy"}], "ancestors": [{"id": "D000001927", "term": "Brain Diseases"}, {"id": "D000002493", "term": "Central Nervous System Diseases"}, {"id": "D000009422", "term": "Nervous System Diseases"}], "browseLeaves": [{"id": "M7983", "name": "Epilepsy", "asFound": "Epilepsy", "relevance": "HIGH"}, {"id": "M5204", "name": "Brain Diseases", "relevance": "LOW"}, {"id": "M5742", "name": "Central Nervous System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077213", "term": "Lamotrigine"}, {"id": "D000078330", "term": "Oxcarbazepine"}, {"id": "D000077287", "term": "Levetiracetam"}, {"id": "C000482793", "term": "Brivaracetam"}, {"id": "C000708857", "term": "Padsevonil"}], "ancestors": [{"id": "D000000927", "term": "Anticonvulsants"}, {"id": "D000018697", "term": "Nootropic Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000026941", "term": "Sodium Channel Blockers"}, {"id": "D000061567", "term": "Voltage-Gated Sodium Channel Blockers"}, {"id": "D000065701", "term": "Cytochrome P-450 CYP3A Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}], "browseLeaves": [{"id": "M1741", "name": "Levetiracetam", "asFound": "Deliver", "relevance": "HIGH"}, {"id": "M249745", "name": "Brivaracetam", "asFound": "Blood sugar", "relevance": "HIGH"}, {"id": "M1701", "name": "Lamotrigine", "asFound": "Muscle strength", "relevance": "HIGH"}, {"id": "M1958", "name": "Oxcarbazepine", "asFound": "Waking", "relevance": "HIGH"}, {"id": "M159917", "name": "Padsevonil", "asFound": "Refractory Lymphoma", "relevance": "HIGH"}, {"id": "M4246", "name": "Anticonvulsants", "relevance": "LOW"}, {"id": "M20774", "name": "Nootropic Agents", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M23177", "name": "Sodium Channel Blockers", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AntiConv", "name": "Anticonvulsants"}, {"abbrev": "NootAg", "name": "Nootropic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}